Identifying biomarkers for prostate cancer patients on active surveillance
Official title: Prognostic Radiomic Signatures in Prostate Cancer Patients on Active Surveillance
Funded at Washington University · NIH-10927436 · Data updated 2026-11-12
This study is looking at new ways to use imaging and molecular tests to find markers that help doctors decide if men with prostate cancer can safely watch their condition instead of starting treatment right away, making it easier and safer for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project start | September 11, 2023 |
| Project end | August 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $162,000 |
| NIH project number | 5K22CA282357-02 |
| Project ID | NIH-10927436 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are men diagnosed with very low, low, or favorable intermediate-risk prostate cancer who are considering active surveillance as a treatment option.
✕Less likely to help
Patients with high-risk prostate cancer or those who have already undergone definitive treatment may not benefit from this research.
What this research studies
This research investigates the use of advanced imaging and molecular techniques to identify biomarkers that can help determine which prostate cancer patients are suitable for active surveillance. By analyzing the interactions between cancer cells and the surrounding extracellular matrix, the study aims to improve the accuracy of monitoring disease progression. Patients will be monitored over time to ensure timely treatment if necessary, reducing the risks associated with immediate invasive procedures. The research utilizes non-invasive methods like MRI and molecular tests to enhance patient outcomes.
Why it matters
Potential benefit: If successful, this research could lead to more accurate monitoring and treatment decisions for prostate cancer patients, potentially improving survival rates and quality of life.
How similar studies have gone: Previous research has shown promise in using biomarkers and imaging techniques for cancer prognosis, suggesting that this approach could yield significant advancements in prostate cancer management.
Where this research is happening
-
Washington University
Saint Louis, United States Active
Researchers
- Principal investigator: Luna Castaneda, Jose Marcio — Washington University
- Study coordinator: Luna Castaneda, Jose Marcio
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.